Due to positive study results Dicot publishes a supplement prospectus

Press release: Uppsala, October 20, 2021. On October 14, 2021 Dicot AB ("Dicot" or the "Company") published positive results from a completed study. Since that publication was made during the subscription period in the ongoing unit rights issue the Company has now established a supplement prospectus (the "Supplement") to the EU growth prospectus related to the invitation to subscribe for units in Dicot with preferential rights which was approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) (''SFSA'') on October 8, 2021 (hereinafter, the "Prospectus"). The Supplement - which was approved by the Swedish Financial Supervisory Authority today October 20, 2021 - forms a part of the Prospectus and shall in all respects be read together with the Prospectus.

By reason of Dicot on October 14, 2021 having published a press release announcing that the Company has completed a study on rats with diabetes and proven erectile dysfunction in which the Company's drug candidate demonstrated significantly improved erection compare to the control group, this Supplement has been prepared. The press release is available at the Company's website, www.dicot.se. The study results were published during the subscription period in the ongoing unit rights issue and have been considered an event which may influence the appraisal of the units offered in the mentioned issue. The Company has therefore established the Supplement pursuant to the content of this press release.

The Supplement has been prepared in accordance with Article 23 of the Regulation (EU) 2017/1129 of the European Parliament and of the Council (the "Prospectus Regulation") and has today October 20, 2021 been approved and registered by the SFSA. The Supplement forms a part of the Prospectus and shall in all respects be read together with the Prospectus. The Prospectus and the Supplement are available on the Company's website (www.dicot.se) and Hagberg & Aneborn Fondkommission AB's website (www.hagberganeborn.se) and will also be available on SFSA's website, www.fi.se.

Investors who before the publication of the Supplement have applied for, or in any other manner consented to, subscription of units in the rights issue have, in accordance with Article 23 of the Prospectus Regulation, the right to withdraw their application or consent within two business days from the publication of the Supplement, i.e. up to and including October 22, 2021. A withdrawal shall be made in writing to Hagberg & Aneborn Fondkommission AB, Matter: Dicot, Valhallavägen 124, 114 41 Stockholm, or by e-mail to [email protected]. Investors who have subscribed for units through a nominee need to contact their nominee for withdrawal. Any subscription or application that is not withdrawn within the time frame above will remain binding and those subscribers who wish to remain with their subscription or application do not need to take any further action. Further instructions on how to withdraw a subscription or an application are to be found in the Supplement.

For complete terms and other information about the rights issue, please refer to the Prospectus and the Supplement.


Stockholm Corporate Finance AB is acting as financial adviser to the Company in the rights issue. Advokatfirman Lindahl KB is acting as the legal adviser to the Company. Hagberg & Aneborn Fondkommission AB is the issuing agent in the rights issue.

For further information, please contact:

Göran Beijer CEO
Tel: +46 706 63 60 09
Email: [email protected]

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 2,250 shareholders. For more information, please visit www.dicot.se.


This press release is not an offer to subscribe for shares or units in Dicot and investors should not subscribe or acquire any securities. Invitation to concerned persons to subscribe for shares in Dicot will only be made through the Prospectus.

This press release shall not, directly or indirectly, be released, published or distributed in or to the United States, Australia Japan, Canada, New Zealand, Hong Kong, South Africa or other country where such action as a whole or in part is subject to legal restrictions. Neither unit rights, units subscribed for ("BTU") or newly issued units have been recommended or approved by any US federal or state securities authority or regulatory authority. No subscription rights, BTA or newly issued shares have been registered or will be registered under the United States Securities Act of 1933, as applicable, or in accordance with applicable laws in the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or in any other country where the rights issue or distribution of the press release is in violation of applicable laws or regulations or presupposes that a further prospectus is established, registered or that any other measure is undertaken beyond that required by Swedish law. The press release, as well as the prospectus, the application form and other documents attributable to the rights issue, may consequently not be distributed to any such jurisdiction.

There is no intention to register any portion of the offer in the United States and the securities issued in the rights issue will not be offered to the public in the United States.

The Company has not authorized any offer to the public with regards to the shares or rights that are referred to in this communication in any member state of the European Economic Area (''EEA'') besides Sweden. This communication is only addressed to and is only directed at qualified investors in other members states within the EEA.

This press release may contain certain forward-looking information that reflects Dicot's current views on future events as well as financial and operational development. Words that are "intended", "come", "judged", "expected", "can", "plan", "appreciate" and other expressions that imply indications or predictions about future developments or trends, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties because it depends on future events and circumstances. Forward-looking information does not constitute a guarantee of future performance or development and actual outcomes may differ substantially from what is stated in forward-looking information. This information, the opinions and the forward-looking statements contained in this press release are valid only on this date and may be amended without notice. Dicot makes no representations about publishing updates or revisions of forward-looking information, future events or similar circumstances other than the applicable law.

Om Dicot Pharma

Dicot utvecklar ett modernt potensläkemedel som ska behandla erektionssvikt och för tidig utlösning bättre än befintliga preparat.



Kurs ()
Förändring ()
Marknad Spotlight Stock Market Kortnamn DICOT ISIN-kod SE0011178458


Elin Trampe Vd